"Hand-Foot Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
| Descriptor ID |
D060831
|
| MeSH Number(s) |
C17.800.174.600.587 C25.100.468.380.587
|
| Concept/Terms |
Hand-Foot Syndrome- Hand-Foot Syndrome
- Hand Foot Syndrome
- Hand-Foot Syndromes
- Syndrome, Hand-Foot
- Syndromes, Hand-Foot
- Chemotherapy-Induced Palmoplantar Erythrodysesthesia
- Chemotherapy Induced Palmoplantar Erythrodysesthesia
- Chemotherapy-Induced Palmoplantar Erythrodysesthesias
- Palmoplantar Erythrodysesthesia, Chemotherapy-Induced
- Palmoplantar Erythrodysesthesias, Chemotherapy-Induced
- Chemotherapy-Induced Acral Erythema
- Acral Erythema, Chemotherapy-Induced
- Acral Erythemas, Chemotherapy-Induced
- Chemotherapy Induced Acral Erythema
- Chemotherapy-Induced Acral Erythemas
|
Below are MeSH descriptors whose meaning is more general than "Hand-Foot Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Hand-Foot Syndrome".
This graph shows the total number of publications written about "Hand-Foot Syndrome" by people in this website by year, and whether "Hand-Foot Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hand-Foot Syndrome" by people in Profiles.
-
Palmoplantar erythrodysesthesia: a diagnostic sign of COVID-19. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):e247-e249.
-
Skin adverse events in recently approved targeted therapies in solid malignancies. Future Oncol. 2019 Jan; 15(3):331-343.
-
Identification of the Novel Capecitabine Metabolites in Capecitabine-Treated Patients with Hand-Foot Syndrome. Chem Res Toxicol. 2018 10 15; 31(10):1069-1079.
-
Topical non-occlusive polymers in hand-foot syndrome. G Ital Dermatol Venereol. 2018 Apr; 153(2):165-171.
-
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018 04; 19(4):451-460.
-
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. Cancer. 2017 Jun 15; 123(12):2294-2302.
-
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2014 Jul; 74(1):77-84.